A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer.

doi:10.1158/1078-0432.CCR-20-1439

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Oct 2020

Wang Yifan, Park Jin Yong Patrick, Pacis Alain, Denroche Robert E, Jang Gun Ho, Zhang Amy, Cuggia Adeline, Domecq Celine, Monlong Jean, Raitses-Gurevich Maria, Grant Robert C, Borgida Ayelet, Holter Spring, Stossel Chani, Bu Simeng, Masoomian Mehdi, Lungu Ilinca M, Bartlett John M S, Wilson Julie M, Gao Zu-Hua, Riazalhosseini Yasser, Asselah Jamil, Bouganim Nathaniel, Cabrera Tatiana, Boucher Louis-Martin, Valenti David, Biagi James, Greenwood Celia M T, Polak Paz, Foulkes William D, Golan Talia, O'Kane Grainne M, Fischer Sandra E, Knox Jennifer J, Gallinger Steven, Zogopoulos George

Abstract excerpt

PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) arising in patients with a germline BRCA1 or BRCA2 (gBRCA) mutation may be sensitive to platinum and PARP inhibitors (PARPi). However, treatment stratification based on gBRCA mutational status alone is associated with heterogeneous responses. EXPERIMENTAL DESIGN: We performed a seven-arm preclinical trial consisting of 471 mice, representing 12 unique PDAC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Cisplatin

Share to Heterografts

Share to Homologous Recombination

Share to Pancreatic Neoplasms

Share to Phthalazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 32816949
DOI: 10.1158/1078-0432.CCR-20-1439

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer.PMID 32816949Read ↗

Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models.Semantic proximity Read ↗

Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.Semantic proximity Read ↗

Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Familial Pancreatic Cancer Research: Bridging Gaps in Basic Research and Clinical ApplicationSemantic proximity Read ↗

Familial Pancreatic Cancer Research: Bridging Gaps in Basic Research and Clinical Application.Semantic proximity Read ↗

Homologous recombination-DNA damage response defects increase TMB and neoantigen load, but not effector T cell density and clonal diversity in pancreatic cancerSemantic proximity Read ↗

Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting.Semantic proximity Read ↗

Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP InhibitionSemantic proximity Read ↗

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer TypesSemantic proximity Read ↗

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient StratificationSemantic proximity Read ↗

Pan-cancer analysis of homologous recombination deficiency and homologous recombination repair–associated gene alterations in solid tumors from a large Asian cohortSemantic proximity Read ↗

Whole Genome Landscape Analysis of Homologous Recombination Deficiency in a Pan-Cancer CohortSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.